New drug SLC-3010 takes on advanced solid tumors
NCT ID NCT05525247
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This trial studies a new drug called SLC-3010, given alone or with chemotherapy (gemcitabine), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. The study is in two parts: first, finding the right dose, then testing that dose in more patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SLC-3010
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early-phase trial with a small number of participants. The drug may not shrink tumors or could cause side effects. Success in this phase does not guarantee later approval.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- DS1025a for Advanced Solid Tumors - Trial NCT07681882
- BiCAP: Continued Access to Bicycle Therapies for NCT07681674
- GFH276 Combo for RAS-Mutant Solid Tumors & PDAC NCT07678593
- SHR-4685 for Solid Tumors Phase 1 Trial NCT07676903
- Long-Term Safety Study of Gotistobart for Advanc NCT07659379
- Tulmimetostat Trial for Advanced Solid Tumors & NCT04104776
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Selecxine Investigator site
Sarasota, Florida, 34232, United States
-
Selecxine Investigator site
Detroit, Michigan, 48201, United States
-
Selecxine Investigator site
Oklahoma City, Oklahoma, 73104, United States
-
Selecxine Investigator site
Waratah, New South Wales, 2298, Australia
-
Selecxine Investigator site
Brentwood, Perth, 6153, Australia
-
Selecxine Investigator site
Seoul, Jongno-gu, 03080, South Korea
-
Selecxine Investigator site
Seoul, Seodaemun-gu, 03722, South Korea
-
Selecxine Investigator site
Gyeonggi-do, Seongnam-si, 13620, South Korea
-
Selecxine Investigator site
Seoul, Songpa-gu, 05505, South Korea